Evaluation of Platelet Antagonists in In Vitro Flow Models of Thrombosis

  • Owen J. T. McCarty
  • James P. Abulencia
  • Shaker A. Mousa
  • Konstantinos Konstantopoulos


Intravascular thrombosis is one of the most frequent pathological events that affects mankind, and a major cause of morbidity and mortality in developed countries. There is abundant evidence suggesting that platelets play a pivotal role in the pathogenesis of arterial thrombotic disorders, including unstable angina (UA), myocardial infarction (MI), and stroke (1, 2, 3). The underlying pathophysiological mechanism of these processes has been recognized as the disruption or erosion of a vulnerable atherosclerotic plaque, leading to local platelet adhesion and subsequent formation of partially or completely occlusive platelet thrombi.


  1. 1.
    Antiplatelet Trialist Collaboration. (1994) Collaborative overview of randomized trials of antiplatelet therapy-I: prevention of death myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Br. Med. J. 308, 81–106.CrossRefGoogle Scholar
  2. 2.
    Fitzgerald, D. J., Roy, L., Catella, F., and Fitzgerald, G. A. (1986) Platelet activation in unstable coronary disease. N. Eng. J. Med. 315, 983–989.CrossRefGoogle Scholar
  3. 3.
    Fuster, V. (1994) Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation 90, 2126–2146.PubMedGoogle Scholar
  4. 4.
    Konstantopoulos, K., Kukreti, S., and McIntire, L. V. (1998) Biomechanics of cell interactions in shear fields. Adv. Drug Delivery Rev. 33, 141–164.CrossRefGoogle Scholar
  5. 5.
    Alevriadou, B. R., Moake, J. L., Turner, N. A., Ruggeri, Z. M., Folie, B. J., Phillips, M. D., et al. (1993) Real-time analysis of shear dependent thrombus formation and its blockade by inhibitors of von Willebrand factor binding to platelets. Blood 81, 1263–1276.PubMedGoogle Scholar
  6. 6.
    Turitto, V. T. (1982) Blood viscosity, mass transport, and thrombogenesis. Prog. Hemostasis Thromb. 6, 139–177.Google Scholar
  7. 7.
    The EPIC Investigators (1994) Use of a monoclonal antibody directed against the glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N. Engl. J. Med. 330, 956–961.CrossRefGoogle Scholar
  8. 8.
    Konstantopoulos, K. and Mousa, S. A. (2001) Antiplatelet therapies: platelet GPIIb/IIIa antagonists and beyond. Current Opinion in Investigational Drugs 2, 1086–1092.PubMedGoogle Scholar
  9. 9.
    Mousa, S. A. (1999) Antiplatelet therapies: recent advances in the development of platelet GPIIb/IIIa antagonists, in Current Interventional Cardiology Reports, Vol. 1. (Holmes, D. R., ed.), Current Science, Philadelphia, PA, pp. 243–252.Google Scholar
  10. 10.
    Peter, K., Schwarz, M., Ylanne, J., Kohler, B., Moser, M., Nordt, T, et al. (1998) Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa inhibitors. Blood 92, 3240–3249.PubMedGoogle Scholar
  11. 11.
    Holmes, M. B., Sobel, B. E., Cannon, C. P., and Schneider, D. J. (2000) Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome. An OPUS-TIMI 16 substudy. Am. J. Cardiol. 85, 491–493.PubMedCrossRefGoogle Scholar
  12. 12.
    Gear, A. R. L. and Lambrecht, J. K. (1981) Reduction in single platelets during primary and secondary aggregation. Thromb. Haemostasis 45, 298.Google Scholar
  13. 13.
    Peterson, D. M., Stathopoulos, N. A., Giorgio, T. D, Hellums, J. D., and Moake, J. L. (1987) Shear-induced platelet aggregation requires von Willebrand factor and platelet membrane glycoproteins Ib and IIb–IIIa. Blood 69, 625–628.PubMedGoogle Scholar
  14. 14.
    Jen, C. J. and McIntire, L. V. (1984) Characteristics of shear-induced aggregation in whole blood. J. Lab. Clin. Med. 103, 115–124.PubMedGoogle Scholar
  15. 15.
    Sweeney, J. D., Labuzzetta, J. W., Michielson, C. E., and Fitzpatrick, J. E. (1989) Whole blood aggregation using impedance and particle counter methods. Am. J. Clin. Pathol. 92, 794–797.PubMedGoogle Scholar
  16. 16.
    Konstantopoulos, K., Kamat, S. G., Schafer, A. I., Bañez, E. I., Jordan, R., Kleiman, N. S., et al. (1995) Shear-Induced Platelet Aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary angioplasty. Circulation 91, 1427–1431.PubMedGoogle Scholar
  17. 17.
    Konstantopoulos, K., Grotta, J. C, Sills, C., Wu, K. K., and Hellums, J. D. (1995) Shear-induced platelet aggregation in normal subjects and stroke patients. Thromb. Haemostasis 74, 1329–1334.Google Scholar
  18. 18.
    Konstantopoulos, K., Wu, K. K, Udden, M. M., Bañez, E. I., Shattil, S. J., and Hellums, J. D. (1995) Flow cytometric studies of platelet responses to shear stress in whole blood. Biorheology 32, 73–93.PubMedGoogle Scholar
  19. 19.
    Abulencia, J. P., Tien, N., McCarty, O. J. T., Plymire, D., Mousa, S. A., and Konstantopoulos, K. (2001) Comparative antiplatelet efficacy of a novel, nonpeptide GPIIb/IIIa antagonist (XV454) and Abciximab (c7E3) in Flow Models of Thrombosis. Arterioscler. Thromb. Vase. Biol. 21, 149–156.CrossRefGoogle Scholar
  20. 20.
    Turner, N. A., Moake, J. A., Kamat, S. G., Schafer, A. I., Kleiman, N. S., and McIntire, L. V. (1995) Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb–IIIa. Circulation 91, 1354–1362.PubMedGoogle Scholar
  21. 21.
    Mousa, S. A., Abulencia, J. P., McCarty, O. J. T., Turner, N. A., and Konstantopoulos, K. (2002) Comparative efficacy between the glycoprotein IIb/IIIa antagonists roxifiban and orbofiban in inhibiting platelet responses in flow models of thrombosis. J. Cardiovasc. Pharmacol. 39, 552–560.PubMedCrossRefGoogle Scholar
  22. 22.
    Evangelista, V., Manarini, S., Rotondo, S., Martelli, N., Polischuk, R., McGregor, J. L., et al. (1996) Platelet/polymorphonuclear leukocyte interaction in dynamic conditions: evidence of adhesion cascade and cross talk between P-selectin and the beta 2 integrin CD11b/CD18. Blood 88, 4183–4194.PubMedGoogle Scholar
  23. 23.
    Folie, B. J., McIntire, L. V., and Lasslo, A. (1988) Effects of a novel antiplatelet agent in mural thrombogenesis on collagen-coated glass. Blood 72, 1393–1400.PubMedGoogle Scholar
  24. 24.
    Ross, J. M., McIntire, L. V., Moake, J. L., and Rand, J. H. (1995) Platelet adhesion and aggregation on human type VI collagen surfaces under physiological flow conditions. Blood 85, 1826–1835.PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2004

Authors and Affiliations

  • Owen J. T. McCarty
    • 1
  • James P. Abulencia
    • 1
  • Shaker A. Mousa
    • 2
  • Konstantinos Konstantopoulos
    • 1
  1. 1.Department of Chemical and Biomolecular EngineeringJohns Hopkins UniversityBaltimore
  2. 2.Albany College of PharmacyAlbany

Personalised recommendations